Related Experiment Video

Updated: Feb 4, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Mouse models for hepatitis B virus research

Jeong-Ryul Hwang1, Sung-Gyoo Park1

  • 1School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea.

Laboratory Animal Research
|October 13, 2018
PubMed

Insights

Hepatitis B virus (HBV) infection affects millions globally. This review details mouse models, like transgenic and chimeric mice, developed to overcome limitations of primate models for studying HBV therapies in vivo.

Area of Science:

  • Hepatology
  • Virology
  • Translational Medicine

Background:

  • Hepatitis B virus (HBV) infection is a significant global health issue with 250 million carriers.
  • Primates are susceptible to HBV but are unsuitable animal models due to ethical, cost, and size constraints.
  • The lack of appropriate in vivo models hinders the development of HBV therapies.

Purpose of the Study:

  • To review and summarize currently available mouse model systems for studying Hepatitis B virus in vivo.
  • To address the need for suitable animal models in HBV research.

Main Methods:

  • Review of existing literature on HBV mouse models.
  • Summary of four main types of mouse models: HBV transgenic mice, hydrodynamic injection-mediated HBV replicon delivery systems, adeno-associated virus-mediated HBV replicon delivery systems, and human liver chimeric mouse models.

Main Results:

  • Several mouse model systems for HBV research are available and under development.
  • These models include transgenic mice, hydrodynamic injection systems, AAV delivery systems, and chimeric mice.
  • These models show promise for in vivo studies of HBV.

Conclusions:

  • Developed mouse models offer viable alternatives to primate models for HBV research.
  • These models are crucial tools for advancing the study of HBV and the development of new therapies.
Keywords:
FRGHepatitis B virusalb-uPA/SCIDmouse model

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Related Concept Videos

What are Viruses?00:50

What are Viruses?

Overview
128.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
299
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
244
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
581